TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Endoscopic Clearance Rate for Barrett's Esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological Clearance Rate for Intestinal Metaplasia (CE-IM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Quality of Life Questionnaire Results
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum tolerated dose of everolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of CaptHPV method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of suspected infections
Endpoint domain: Adverse events/effects
Primary endpoint: evolution in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: time to recovery following sugammadex administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of post-operative GERD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction and or elimination of co-morbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickness of musculus serratus anterior
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Thickness of musculus trapezius
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Thickness of musculus rhomboideus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cross sectional area of nervus thoracicus longus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cross sectional area of nervus accesorius
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnosis of Celiac Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total pain relief 0-4 hours after study medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference between set pressure and measured pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the tissue containment system
Endpoint domain: Adverse events/effects
Primary endpoint: Renal function measured by Cystatin-C and creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Bone mass assessed by DEXA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Support of a Label
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effective Radiation Dose Following Injection of 18F-JNJ-64413739
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total and Regional Brain Compartmental Kinetics for Volume of Distribution of 18F-JNJ-64413739
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentrations of JNJ-54175446
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of urge urinary incontinence episodes per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: total number of urinary incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: total void frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Volitional Response Index Magnitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type of Bleed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spot Sign Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amyloid uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in mean serum iPTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With Completely Healed Lower Extremity Wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Achieving Serum HBV DNA Level of <300 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Internal consistency of the SCPI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Validity of the SCPI with HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of Laryngeal Vestibule Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laryngeal Vestibule Closure Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of net adverse clinical events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Fast blood glucose (FBG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postmeal blood glucose (PBG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of anti-B. burgdorferi IgG / IgM antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall kappa opioid receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effusion-synovitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS knee pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: emotion regulation ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High resolution imaging of the visual pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virus RNA detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Macrophage phenotype and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dendritic cell phenotype and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of COPD exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Antibody Responses Pre- and Post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of Anti-diphtheria, Anti-tetanus, and Anti-pertussis Toxoids Pre- and Post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reactogenicity in Terms of Solicited Symptoms After Dose 1 of the Dengue Vaccine vs. Control Vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titers (GMT) for N Antibody to All Four Serotypes and Japanese Encephalitis (JE) Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent of Participants With Seronegative Neutralizing (N) Antibody Titers to Each DEN Serotype After Dose 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage change from baseline of inflammatory acne lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Total recovery of radioactive dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate and routes of excretion of total radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolic pattern and metabolic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Score on Disease Activity Score Based on 28-Joints Count at Visit 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Pain Visual Analog Scale Score at Visit 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician's Global Assessment of Disease Activity at Visit 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain as measured by the WOMAC Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve lowest oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Factor VIII inhibitor formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Genome sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dichotomized treatment response based on bone scintigraphy intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dichotomized treatment response based on CT lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dichotomized treatment response based on ALP measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of lung aspiration
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence and incidence of malignant pancreatic cysts
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of spontaneous abortion before 28 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of bone marrow failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CCPP (Chronic Pelvic Pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of synovial effusion and/or synovial hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Presence of bone erosion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: CGI-I (clinical global impression-I)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: ASRS (Adult ADHD Self Report Scale)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Facial recognition test
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Incidence of DMD
Endpoint domain: Adverse events/effects
Primary endpoint: morphological changes of the developing fetal brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline in ZAN-BPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engagement level
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Rate of Torque Increase, Flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of Torque Increase, Extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Disease location prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Emergence delirium (ED)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients needing further treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of lesions with Calcium Fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: percent change from baseline to average triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary Glucose Excretion (UGE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reproductive concerns
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Time to hemodialysis catheter-related bacteremia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Negative Breath Alcohol and Urine Drug Screens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy value of almonds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient complete or partial clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion-specific clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Program effectiveness
Endpoint domain: Life impact
Primary endpoint: Safety and tolerability of ADP-A2M4CD8
Endpoint domain: Adverse events/effects
Primary endpoint: Any clinical or laboratory adverse experience
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Meeting the Definition of Improvement (DOI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Age- and Sex-adjusted BMI% Greater Than or Equal to 85%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of GDC-0575
Endpoint domain: Adverse events/effects
Primary endpoint: Performance in standardized speech perception tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vaginal delivery within 24 hours
Endpoint domain: Mortality/survival
Primary endpoint: ripening success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Unintended Pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: transplant free survival at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: accuracy of procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antiretroviral Therapy (ARV) adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: visual information processing speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: DNA methylation of CD3+ T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients not reaching criteria to resume antiretroviral treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 3-year disease-free survival rate (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity and Specificity of High Resolution Versus Standard MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Receiver Operator Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Medically Attended Adverse Events (MAEs), potential Immune Mediated Diseases (pIMDs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Stents With Successful Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Freedom From Occurrence of Death, Amputation and TVR/TLR at 30-days Post-index Procedure
Endpoint domain: Mortality/survival
Primary endpoint: Complete Clearance of Baseline External Genital and Perianal Warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Bone Mineral Density (BMD) at the Lumbar Spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: size assessment of known malignant lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnosis of BI-RADS 3 and 4 breast lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: diagnosis of suspected rupture of breast implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Albuminuria/urinary creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of new genes identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile of MN-166 (ibudilast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Post-operative Severe Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Nurses' work environment
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: change in Beliefs- attitudes and behavior in front of EBP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intensive care Length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Thickening fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of resting gallbladder volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: radiographic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Death and Cardiovascular Events
Endpoint domain: Mortality/survival
Primary endpoint: Dimensions of acne scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Exudate Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence and severity of pruritus
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Progression-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of subjects meeting responder criteria based on IGF-1 measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Daytime arterial carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: time to returning to daily activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ΔHb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quality of Patient Clinician Communication About End-of-Life Care
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline Depressive Symptoms at 6 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline Anxiety Symptoms at 6 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of progression to diabetes
Endpoint domain: Mortality/survival
Primary endpoint: time to the development of brain metastasis
Endpoint domain: Mortality/survival
Primary endpoint: synovitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: enthesitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: joint erosion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: osteophyte/ cortical irregularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: enthesophyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of the POEM procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time In Range (TIR) for blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fetal Body Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal Brain Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Start/Switch Disease Modifying Therapy (DMT)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Immediate refit success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean office SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: favorable best response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in abdominal obesity measured by waist circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Any, Grade 3 and Related Medically Significant Conditions (MSCs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Pregnancies and Pregnancy Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: improvement of ADHD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression: ADHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of acute toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Time from sedation discontinuation to first T-Tube placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: maximum tolerated dose (MTD) of defactinib in combination with avelumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: best overall response according to RECIST version 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proprioception test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Torque & Peak Torque/Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Closed kinetic chain upper extremity stability test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified push-up test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum nitric oxide (NO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum Endothelin-1 (ET-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum plasminogen activator inhibitor-1 (PAI-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes